Workflow #1996

✓ Completed
Type: scraped_article_processing
Started: December 04, 2025 at 2:20:12 AM
Completed: December 04, 2025 at 12:35:42 PM
Completed in 615m 30s
Triggered by: ingestion

Job Pipeline

clean_markdown_article
✓ completed
analyze_article
✓ completed
extract_entities
✓ completed
analyze_sentiment
⊘ skipped

clean_markdown_article

✓ CompletedCompleted in 525m 0s
River Jobs: 1
River Job #30763View LLM Log →

analyze_article

✓ CompletedPending
River Jobs: 1
River Job #33174View LLM Log →

extract_entities

✓ CompletedPending
River Jobs: 1
River Job #33195View LLM Log →

analyze_sentiment

⊘ SkippedSkipped

Workflow Context

title:FDA appoints Tracy Hoeg as acting director of drug evaluation center
source:Reuters
content:![CDC advisory panel for vaccines convenes in Atlanta](https://www.reuters.com/resizer/v2/3VOYZAKSYJNERHZJHL2JWUFSRU.jpg?auth=1379d7d68dad6e14fe13fd7853537cf5841feacc1c4800c5f600abdb57264de7&width=5479&quality=80) Senior Advisor for Clinical Sciences at the FDA Tracy Beth Hoeg, MD, PhD, speaks at the meeting of the members of the Advisory Committee on Immunization Practices as the U.S. Centers for Disease Control and Prevention's (CDC) advisory panel for vaccines convenes, in Atlanta, Georgia, U.S. June 25, 2025.  REUTERS/Megan Varner * Companies * [U.S. Food and Drug Administration](/company/u-s-food-and-drug-administration/) Follow Dec 3 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has appointed Tracy Beth Hoeg as acting director of the Center for Drug Evaluation and Research, after the sudden [retirement](/business/healthcare-pharmaceuticals/newly-appointed-drug-evaluation-chief-set-leave-fda-stat-news-reports-2025-12-02/) of Richard Pazdur just weeks after he assumed the role. Pazdur, the veteran oncology chief at the regulatory agency, took over the role on November 11, after George Tidmarsh resigned amid serious concerns about his personal conduct. Sign up [here.](undefined?location=article-paragraph&redirectUrl=%2Fbusiness%2Fhealthcare-pharmaceuticals%2Ffda-appoints-tracy-heg-acting-director-drug-evaluation-segment-2025-12-04%2F) The appointment of Hoeg, a COVID vaccine skeptic and close aide to FDA Commissioner Marty Makary, comes as U.S. Health Secretary Robert Kennedy Jr. makes stark changes at the agency. "Dr. Hoeg is the right scientist to fully modernize CDER and finish the job of establishing a culture of cross-center coordination there," Makary said. Hoeg assumes the role at a time when the U.S. health regulator has been making sweeping changes on vaccines. A panel will vote this week on whether to delay [hepatitis B shots](/legal/litigation/us-vaccine-committee-vote-this-week-delay-hepatitis-b-shots-2025-12-02/) for most American children, a move that would be the most consequential change since the health secretary began remaking vaccine policy. CDER is the FDA's largest and most important division, which regulates over-the-counter and most prescription drugs. Hoeg, who opposed key U.S. health policies during the COVID-19 pandemic and questioned the use of some childhood vaccines, was named a special assistant to Makary in April. A physician and epidemiologist, Hoeg has also practiced physical and interventional spine and sports medicine before joining the FDA as senior adviser for clinical sciences in the office of the commissioner and the Center for Biologics Evaluation and Research. Both Hoeg and Makary expressed contrarian views on U.S. COVID policies, including opposition to mask requirements for children and universal vaccine mandates for the public, while supporting vaccination in general as a key public health measure. Reporting by Sriparna Roy and Angela Christy in Bengaluru; Editing by Sherry Jacob-Phillips Our Standards: [The Thomson Reuters Trust Principles., opens new tab](https://www.thomsonreuters.com/en/about-us/trust-principles.html) * Suggested Topics: * [Healthcare & Pharmaceuticals](/business/healthcare-pharmaceuticals/) * [Regulatory Oversight](/sustainability/regulatory-oversight/) * [Regulatory](/business/healthcare-pharmaceuticals/regulatory/) * [Corporate Structure](/business/healthcare-pharmaceuticals/corporate-structure/) * [Approvals](/business/healthcare-pharmaceuticals/approvals/) Share * X * Facebook * Linkedin * Email * Link Read Next --------- * ago[Healthcare & Pharmaceuticalscategory](/business/healthcare-pharmaceuticals/) [Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment](/business/healthcare-pharmaceuticals/details-failed-studies-cast-pall-novo-nordisks-glp-1-alzheimers-treatment-2025-12-04/) [![Novo Nordisk offices in Bagsvaerd](https://www.reuters.com/resizer/v2/TO7HLSBMAZMC5PEPHUCS2ZPVHQ.jpg?auth=47808cf9d4d5b5939913f2cf088f6b06f3e8a71bdb69b6948eda71470862c5ab&width=1200&quality=80)](/business/healthcare-pharmaceuticals/details-failed-studies-cast-pall-novo-nordisks-glp-1-alzheimers-treatment-2025-12-04/) * ago[Healthcare & Pharmaceuticalscategory](/business/healthcare-pharmaceuticals/) [FDA approves Axogen's nerve repair graft](/business/healthcare-pharmaceuticals/fda-approves-axogens-nerve-repair-graft-2025-12-03/) [![Signage is seen outside of FDA headquarters in White Oak, Maryland](https://www.reuters.com/resizer/v2/VH5RAL6YVBNWHKTBH3FWDY63SA.jpg?auth=d4470d31fcd6faff95426d892ecf137677db5ca2337eb6277db2b057a46b6016&width=1200&quality=80)](/business/healthcare-pharmaceuticals/fda-approves-axogens-nerve-repair-graft-2025-12-03/) * ago[Healthcare & Pharmaceuticalscategory](/business/healthcare-pharmaceuticals/) [US FDA removes longtime director of over-the-counter drugs office](/business/healthcare-pharmaceuticals/us-fda-removes-longtime-director-over-the-counter-drugs-office-2025-12-03/) [![Signage is seen outside of FDA headquarters in White Oak, Maryland](https://www.reuters.com/resizer/v2/4JFQPAUPOFNCTGYMT7YL4TJSEY.jpg?auth=39bfe6eb8c7363e343937eda3027a5ae59c4f87f4e0e40eae719d45762b66cd8&width=1200&quality=80)](/business/healthcare-pharmaceuticals/us-fda-removes-longtime-director-over-the-counter-drugs-office-2025-12-03/) * ago[Healthcare & Pharmaceuticalscategory](/business/healthcare-pharmaceuticals/) [Anabel's lost year illustrates the failings of Spain's breast cancer program](/business/healthcare-pharmaceuticals/anabels-lost-year-illustrates-failings-spains-breast-cancer-program-2025-12-03/) [![Anabel's lost year: Spain's breast cancer screening failure could affect thousands](https://www.reuters.com/resizer/v2/VMR6YBN6NZP7RBEAHSVN764JLY.jpg?auth=575ec555e7283534406458629c5bf14472d1bed008a8ac70ec80802c7806472d&width=1200&quality=80)](/business/healthcare-pharmaceuticals/anabels-lost-year-illustrates-failings-spains-breast-cancer-program-2025-12-03/) * ago[Healthcare & Pharmaceuticalscategory](/business/healthcare-pharmaceuticals/) [Novo Nordisk gears up for December Ozempic launch in India, sources say](/business/healthcare-pharmaceuticals/novo-nordisk-gears-up-december-ozempic-launch-india-sources-say-2025-12-03/) [![FILE PHOTO: A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London](https://www.reuters.com/resizer/v2/WMAWOBMJPJJDHCVIO2PT3NCP3E.jpg?auth=f050c9e17632285b125092f1ceb887ed8df0206e2c2018188b16a3347df0041e&width=1200&quality=80)](/business/healthcare-pharmaceuticals/novo-nordisk-gears-up-december-ozempic-launch-india-sources-say-2025-12-03/) [![LSEG Workspace](https://cloudfront-us-east-2.images.arcpublishing.com/reuters/AE6BNNRLSVAQTFG5XHTC4AV6YI.jpg)](https://www.lseg.com/en/data-analytics/products/workspace?utm_source=reuters.com&utm_medium=articlebanner&utm_campaign=Reuters_ProductPage_Links) ---------------------- * [](/world/india/indian-rupee-rise-record-lows-us-trade-deal-key-recovery-2025-12-04/) ### [Indian rupee to rise from record lows, but US trade deal key for recovery](/world/india/indian-rupee-rise-record-lows-us-trade-deal-key-recovery-2025-12-04/) [category](/world/) · December 4, 2025 · 2:14 AM UTC · ago The Indian rupee will regain some lost ground against the U.S. dollar over the next three months, according to a Reuters poll of FX strategists, but a reversal in the currency's fortunes hinges upon India and the U.S. agreeing to a trade deal. * [![U.S. dollar notes are seen in this picture illustration](https://www.reuters.com/resizer/v2/A32SESR7HBKQTLY66OEAET2RTY.jpg?auth=6aa06727355ce473d95db896f7cfe535137f91fd9a25e395e73d6a3f0865e6b4&width=960&quality=80)](/world/asia-pacific/dollar-weak-with-rate-cut-enthusiasm-intact-euro-7-week-high-2025-12-04/) [category](/world/)[Dollar weak with rate-cut enthusiasm intact, euro at 7-week high](/world/asia-pacific/dollar-weak-with-rate-cut-enthusiasm-intact-euro-7-week-high-2025-12-04/) 1:43 AM UTC * [![An Australia and New Zealand Banking Group Limited (ANZ) logo is displayed in a branch window in Sydney](https://www.reuters.com/resizer/v2/FT5AM2AX3JLJHLZRXBX7YLQGP4.jpg?auth=15d2ec6d1c3f34a3d604d11c8b779de179b966e1881c69846d020434b617d64a&width=960&quality=80)](/sustainability/boards-policy-regulation/second-anz-proxy-advisor-recommends-vote-against-pay-report-2025-12-04/) [Sustainabilitycategory](/sustainability/)[Second ANZ proxy advisor recommends vote against pay report](/sustainability/boards-policy-regulation/second-anz-proxy-advisor-recommends-vote-against-pay-report-2025-12-04/) 1:41 AM UTC * [![A view shows oil pump jacks outside Almetyevsk](https://www.reuters.com/resizer/v2/DFOOOE4MJVJ4FM3WMKLFSZE5FQ.jpg?auth=d43b1d35fb4581037564780a7076682cef74f013a03326df023df771b55569ba&width=960&quality=80)](/business/energy/oil-prices-firm-after-ukrainian-strikes-russian-oil-infrastructure-stalled-peace-2025-12-04/) [Energycategory](/business/energy/)[Oil prices firm after Ukrainian strikes on Russian oil infrastructure, stalled peace talks](/business/energy/oil-prices-firm-after-ukrainian-strikes-russian-oil-infrastructure-stalled-peace-2025-12-04/) 1:27 AM UTC * [](/business/tricolor-creditors-seek-probe-into-alleged-collateral-fraud-lender-conduct-2025-12-04/) [Businesscategory](/business/)[Tricolor creditors seek probe into alleged collateral fraud, lender conduct](/business/tricolor-creditors-seek-probe-into-alleged-collateral-fraud-lender-conduct-2025-12-04/) 1:18 AM UTC
article_id:2872 →
content_type:article